HealthEconomics.Com Founder and CEO Dr. Patti Peeples recently spoke with Panalgo’s Matt Sussman regarding changes to the value assessments carried out by the Institute for Clinical and Economic Review (ICER). Real world evidence (RWE) and real world data (RWD) are gaining prominence while the revised cost-effectiveness threshold of $200,000 per quality Quality-Adjusted Life Year is a positive change. Panalgo will sponsor a webinar on November 17thon ICER’s review process with insight from a diverse group of stakeholders, including Dan Ollendorf of the Center for the Evaluation of Value and Risk in Health.
“Because ICER decisions have significant market access and business implications, it is critical that biopharma teams plan for an early, ongoing and comprehensive ICER engagement strategy.” Read more here.
(Source: tHEORetically Speaking–HealthEconomics.Com, 10/21)